Can-Fite Biopharma

Clinical trials sponsored by Can-Fite Biopharma, explained in plain language.

Can-Fite Biopharma CANF NYSE AMERICAN

A biopharmaceutical company developing drugs for inflammatory and cancer indications.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Promising drug aims to slow kidney damage in rare lowe syndrome Results expected Aug 2027 (estimated) May already have reported ↗

Browse trials soon ready across all sponsors →

Not yet recruiting 1

Promising drug aims to slow kidney damage in rare lowe syndrome

Disease control Not yet recruiting

This early study tests a drug called piclidenoson in 5 adult men with Lowe syndrome, a rare genetic disorder that harms the kidneys. The goal is to see if the drug can improve how the kidneys reabsorb important small proteins over 6 months. Researchers will also check safety and …

Phase 2 • Sponsor: Can-Fite BioPharma • Aim: Disease control

Last updated Jun 27, 2026 09:05 UTC

Can-Fite Biopharma

Upcoming readouts

Promising drug aims to slow kidney damage in rare lowe syndrome